-
Alimera Sciences Inc. (NASDAQ:ALIM), Alpharetta, Ga. pSivida Corp. (NASDAQ:PSDV; ASX:PVA), Watertown, Mass. Business: Ophthalmic Alimera launched Iluvien fluocinolone acetonide intravitreal implant in Germany to treat …
Published on 5/13/2013
-
Biotie Therapies Corp. (HSE:BTH1V), Turku, Finland H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Business: Neurology H. Lundbeck launched Selincro nalmefene in the U.K. to reduce alcohol consumption in adults with …
Published on 5/13/2013
-
Cancer Genetics Inc. (OTCBB:CGIX), Rutherford, N.J. Business: Diagnostic Cancer Genetics launched its genomic microarray UroGenRA Kidney for kidney cancer diagnosis, subtyping and treatment selection. The assay is CLIA …
Published on 5/13/2013
-
Concordia Pharmaceuticals Inc., Fort Lauderdale, Fla. Shionogi & Co. Ltd. (Tokyo:4507; Osaka:4507), Osaka, Japan Business: Pharmaceuticals Concordia acquired from Shionogi rights to ADHD drug Kapvay clonidine and oral …
Published on 5/13/2013
-
Cornerstone Therapeutics Inc. (NASDAQ:CRTX), Cary, N.C. Digestive Care Inc., Bethlehem, Pa. Business: Gastrointestinal Digestive Care granted Cornerstone exclusive, U.S. rights to market Pertzye pancrelipase for 10 …
Published on 5/13/2013
-
Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506; Osaka:4506), Osaka, Japan Ono Pharmaceutical Co. Ltd. (Tokyo:4528; Osaka:4528), Osaka, Japan Business: Neurology The pharmas expanded a 2011 deal to co-develop and co-…
Published on 5/13/2013
-
Genomic Health Inc. (NASDAQ:GHDX), Redwood City, Calif. Business: Diagnostic Genomic Health launched its Oncotype DX prostate cancer assay worldwide to predict adverse pathology in patients with early stage, low-risk …
Published on 5/13/2013
-
Intas Pharmaceuticals Ltd., Ahmedabad, India Business: Biosimilars, Cancer Intas launched Mabtas rituximab in India to treat non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) alone or in combination …
Published on 5/13/2013
-
Martindale Pharma, Brentwood, U.K. Business: Neurology, Drug delivery Martindale launched Prenoxad Injection naloxone hydrochloride in the U.K. to treat acute opioid-related overdose. The product, which costs 18 ($28.05…
Published on 5/13/2013
-
Paladin Labs Inc. (TSX:PLB), Montreal, Quebec Pernix Therapeutics Holdings Inc. (NASDAQ:PTX), the Woodlands, Texas Business: Neurology Paladin launched Silenor doxepin in Canada for the treatment and symptomatic relief …
Published on 5/13/2013
-
Shionogi & Co. Ltd. (Tokyo:4507; Osaka:4507), Osaka, Japan Business: Endocrine/Metabolic Shionogi launched Osphena ospemifene in the U.S. to treat moderate to severe dyspareunia due to postmenopausal vulvovaginal …
Published on 5/13/2013
-
Galderma S.A., Lausanne, Switzerland Business: Dermatology Galderma launched Tri-Luma cream in the U.S. to treat moderate to severe melisma of the face for up to eight weeks. Tri-Luma is a topical combination of …
Published on 2/18/2013
-
Hisamitsu Pharmaceutical Co. Inc. (Tokyo:4530; Osaka:4530), Tosu, Japan Business: Endocrine/Metabolic Hisamitsu's Noven Pharmaceuticals Inc. subsidiary launched Minivelle estradiol transdermal system in the U.S. to …
Published on 2/18/2013
-
Hyperion Therapeutics Inc. (NASDAQ:HPTX), South San Francisco, Calif. Business: Endocrine/Metabolic On a Feb. 4 conference call regarding FDA's approval of Ravicti glycerol phenylbutyrate, Hyperion said it estimated a …
Published on 2/18/2013
-
Innovus Pharmaceuticals Inc. (OTCBB:INNV), San Diego, Calif. Prospector Capital Partners II LLC, San Diego, Calif. Business: Gastrointestinal, Dermatology Innovus signed a binding term sheet to acquire nine prescription…
Published on 2/18/2013
-
Myriad Genetics Inc. (NASDAQ:MYGN), Salt Lake City, Utah Saladax Biomedical Inc., Bethlehem, Pa. Business: Diagnostic Saladax said Myriad will return North American rights to its My5-FU diagnostic test following a …
Published on 2/18/2013
-
Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Business: Endocrine/Metabolic Novo Nordisk said it will launch diabetes drug Tresiba insulin degludec in Japan "shortly after" the drug is listed on Japan's …
Published on 2/18/2013
-
Reckitt Benckiser Group plc (LSE:RB), Slough, U.K. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Pharmaceuticals Reckitt Benckiser will acquire exclusive commercialization and distribution rights to OTC …
Published on 2/18/2013
-
American International Biotechnology LLC, Richmond, Va. Business: Diagnostic The company launched its LDT asparaginase assay in the U.S. and Canada. The assay measures L-asparaginase levels in patients receiving …
Published on 2/11/2013
-
Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Endocrine/Metabolic, Infectious Astellas said in its fiscal 3Q earnings for the period ending Dec. 31, 2012 that it launched three products. Astellas said that …
Published on 2/11/2013
-
Biotest AG (Xetra:BIO), Dreieich, Germany Business: Autoimmune, Diagnostic Biotest's Biotest Pharmaceuticals Corp. subsidiary launched IV Bivigam 10% human immune globulin in U.S. to treat primary immune deficiency …
Published on 2/11/2013
-
Dyax Corp. (NASDAQ:DYAX), Burlington, Mass. Novellus Biopharma AG, Switzerland Business: Inflammation Dyax and Novellus partnered to develop and commercialize Kalbitor ecallantide in select regions in Latin America to …
Published on 2/11/2013
-
Oasmia Pharmaceutical AB (SSE:OASM A), Uppsala, Sweden Pharmasyntez, Irkutsk, Russia Business: Cancer Oasmia granted Pharmasyntez exclusive commercialization and distribution rights to Paclical micellular paclitaxel in …
Published on 2/11/2013
-
Sequenom Inc. (NASDAQ:SQNM), San Diego, Calif. Business: Diagnostic Sequenom said it expanded the range of chromosomal abnormalities reported by the MaterniT21 Plus laboratory-developed test (LDT) to include fetal sex …
Published on 2/11/2013
-
Supernus Pharmaceuticals Inc. (NASDAQ:SUPN), Rockville, Md. Business: Neurology Supernus launched Oxtellar XR oxcarbazepine in the U.S. as an adjunctive therapy in the treatment of partial seizures in adults and …
Published on 2/11/2013